AlloVir (NASDAQ:ALVR – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10, reports.
AlloVir Stock Down 1.8 %
Shares of AlloVir stock opened at $0.55 on Friday. AlloVir has a 52-week low of $0.53 and a 52-week high of $2.49. The firm’s 50 day moving average price is $0.79 and its 200-day moving average price is $0.77.
Institutional Trading of AlloVir
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC increased its position in AlloVir by 152.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock valued at $36,000 after buying an additional 30,072 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in AlloVir during the 2nd quarter valued at approximately $55,000. Price T Rowe Associates Inc. MD lifted its stake in shares of AlloVir by 127.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after buying an additional 54,900 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in shares of AlloVir by 694.6% during the first quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock valued at $1,197,000 after buying an additional 1,387,666 shares during the last quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.
AlloVir Company Profile
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Recommended Stories
- Five stocks we like better than AlloVir
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Why Meta Should Rally All The Way Into 2025
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
